Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07016178 · ClinicalTrials.gov registry record · NA
Innovative Cognitive Impairment Case Finding and Engagement for Diverse Participation in Alzheimer's Disease Care, Treatment, And Research
A NA study, sponsored by Indiana University.
- Completed
- Registry status
- NA
- Development phase
- 3,454
- Enrollment target
NCT07016178: Completed NA study, sponsored by Indiana University.
NCT07016178 is a NA study that has completed, run by Indiana University. The registered enrollment target is 3,454 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (146% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07016178, a NA study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- NA
- Development phase
- 3,454 participants
- Enrollment target
Study Summary
Recent studies have highlighted the potential use of electronic health record (EHR) data for scalable and less biased identification of people who may have or be at risk of developing MCI or ADRD at the population level.8,9 Using data from the EHR in advance of PC visits can systematically identify patients with undetected MCI and ADRD. At Indiana University (IU), researchers developed a Passive Digital Marker (PDM) to enable early detection of ADRD with an 80% accuracy for one-year and three-year prediction horizons.8,9 Despite the accuracy of the PDM, the feasibility, acceptability, and overall effectiveness of its use for early detection of ADRD in PC remains unclear. Building on this innovative tool and the ongoing engagement in IUH PC for early detection of ADRD, we propose a project to test the acceptability and feasibility of implementing the PDM in IUH PC to identify people with and at risk of MCI and ADRD and measure if we can increase patient engagement in research and evidence-based follow-up care with the IUH Brain Health Navigator (BHN). The BHN, is primary care based registered nurse with special training to conduct additional assessments of patients following a positive ADRD screen to identify possible underlying causes of cognitive impairment and assist the PCP to facilitate the patient's next steps for diagnostic assessment.
Primary Outcome
Implement the PDM, using IUH EHR data, to identify primary care patients aged 65 or older who a have undetected MCI or ADRD or who are at risk. Measured by the number of patients identified as high-risk by the PDM.
Interventions
- BEHAVIORAL Acceptability and Feasibility of Twistle messaging for PDM+ patients
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,454 participants |
| Start Date | 2025-10-13 |
| Est. Completion | 2026-01-15 |
| Phase | NA |
What the finished NCT07016178 record still lists
NCT07016178 is an interventional study that assigns participants to a tested intervention. Its 3,454 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (146% higher).
The record links to 0 conditions, and to 1 intervention - of which Acceptability and Feasibility of Twistle messaging for PDM+ patients is the first listed.
NCT07016178 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07016178 about?
NCT07016178 is a clinical study titled "Innovative Cognitive Impairment Case Finding and Engagement for Diverse Participation in Alzheimer's Disease Care, Treatment, And Research". Recent studies have highlighted the potential use of electronic health record (EHR) data for scalable and less biased identification of people who may have or be at risk of developing MCI or ADRD at the population level.8,9 Using data from the EHR in advance of PC visits can systematically identify ...
What is the current status of trial NCT07016178?
This trial is currently completed. It is a NA study. The enrollment target is 3,454 participants. The study started on 2025-10-13. Estimated completion is 2026-01-15.
What interventions are being tested in trial NCT07016178?
The interventions under investigation include: Acceptability and Feasibility of Twistle messaging for PDM+ patients (BEHAVIORAL).
Who is sponsoring clinical trial NCT07016178?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07016178's enrollment target sits among peer trials
3,454 37th of 2000 higher than 1,964 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00260559 · 3,500 participants
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
- NCT01612949 · 3,500 participants
Facial Analysis to Classify Difficult Intubation
- NCT02398786 · 3,500 participants
Myotonic Dystrophy Family Registry
- NCT03486873 · 3,500 participants · Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI